Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Recruiting 3Completed 2Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 5NIH 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Breast Neoplasms 15Triple Negative Breast Neoplasms 9Neoplasms 8Prostatic Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Polycythemia Vera 1Pathologic Complete Response 1Osteosarcoma 1Neuroendocrine Tumors 1

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × talazoparib × Clear all
NCT04846478 2026-05-12

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
35 enrolled
Genitourinary

Prostatic Neoplasms

NCT05873192 2026-05-05

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT06844383 2026-04-24

TALENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Recruiting
126 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

City of Hope Medical Center

Phase 2 Recruiting
70 enrolled
Genitourinary

Prostatic Neoplasms

NCT04019327 2025-12-15

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
16 enrolled
Genitourinary

Prostatic Neoplasms

NCT04332744 2025-05-11

ZZ-First

MedSIR

Phase 2 Completed
54 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡